首页> 外文期刊>Annals of surgical oncology >Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction.
【24h】

Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction.

机译:保留皮肤的乳房切除术和即刻乳房再造的局部复发的表现,治疗和结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The local recurrence (LR) rate with skin-sparing mastectomy (SSM) and immediate breast reconstruction (IBR) has been reported as comparable to the LR rate after conventional mastectomy. However, limited data are available on the prognostic significance and management of LR following SSM. METHODS: A prospective database maintained at the University of Texas M. D. Anderson Cancer Center identified 437 SSMs performed for 372 invasive T1/T2 breast cancers between 1986 and 1993. RESULTS: Twenty-three LRs were identified, with a LR rate of 6.2% (23/372). Twenty-two of these (96%) presented as palpable skin-flap masses. The median time to recurrence was 25 months (range, 3 to 98 months). Fourteen patients were treated with a combination of surgery and systemic therapy. Resection of the reconstructed breast was performed in only three patients. Complete local control of the recurrent disease was achieved in 17 patients (74%). Nine patients (39%) developed distant metastatic disease. At a median follow-up of 26 months, 14 of 23 patients (61%) are alive without evidence of disease, and 7 (30%) have died from breast cancer. CONCLUSIONS: Because LR rate with SSM is low and likelihood of local control and survival is high, SSM and IBR is an acceptable treatment option for early stage breast cancer.
机译:背景:据报道,保留皮肤的乳房切除术(SSM)和即刻乳房再造(IBR)的局部复发(LR)率与常规乳房切除术后的LR率相当。但是,关于SSM后LR的预后意义和治疗的可用数据有限。方法:得克萨斯大学MD安德森癌症中心维护的前瞻性数据库确定了1986年至1993年之间对372例浸润性T1 / T2乳腺癌进行的437例SSM。结果:确定了23例LR,LR率为6.2%(23 / 372)。其中有二十二个(96%)表现为明显的皮瓣肿块。中位复发时间为25个月(范围3到98个月)。 14例患者接受了手术和全身治疗相结合的治疗。仅三名患者进行了乳房再造术。 17例患者(74%)实现了对复发性疾病的完全局部控制。 9名患者(39%)发生远处转移性疾病。在26个月的中位随访中,23例患者中有14例(61%)活着而没有疾病证据,而7例(30%)因乳腺癌死亡。结论:由于SSM的LR率低,局部控制和生存的可能性高,因此SSM和IBR是早期乳腺癌的可接受治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号